ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023
Hair loss during and after breast cancer therapy.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Chemotherapy-induced alopecia: an exploratory questionnaire-based study from Israel comparing knowledge, attitudes, and management practices among dermatologists and oncologists.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- The use of oral dutasteride, minoxidil, and finasteride for treating endocrine therapy-induced hair loss from breast cancer treatment: A case series study.JAAD case reports · 2026Article
- Chlorpromazine versus Metoclopramide for Neurogenic Nausea and Vomiting in Incurable Patients with Gastrointestinal Tumors: A Prospective Observational Cohort Study.Cancer management and research · 2026Article
- Identifying Core Symptoms in Breast Cancer Patients with Different Chemotherapy Phases Using Network Analysis: A Prospective Multicenter Longitudinal Study.Patient preference and adherence · 2026Article
- Safety First: A Comprehensive Review of Nutritional Supplements for Hair Loss in Breast Cancer Patients.Nutrients · 2025Review
- Approaches to management of endocrine therapy-induced alopecia in breast cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Review
- Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens.Cancers · 2025Review
- Madarosis Among Breast Cancer Survivors.Clinical breast cancer · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For patients diagnosed with breast cancer, alopecia can be a distressing side effect of treatment. Major surgeries, cytotoxic chemotherapy, and endocrine therapy may result in several different types of alopecia. This article reviews the underlying mechanisms, etiology, prevention strategies, and treatment options for chemotherapy-induced alopecia, telogen effluvium, and endocrine-induced alopecia. Here, we aim to provide breast oncologists with a review of the types of hair loss related to cancer therapy and current preventative and treatment options to facilitate informative patient counseling.
Indexed as
Identifiers
36826602What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.